IL‑33 levels differentiate tuberculous pleurisy from malignant pleural effusions

Xuan,Wei‑Xia; Zhang,Jian‑Chu; Zhou,Qiong; Yang,Wei‑Bing; Ma,Li‑Jun

doi:10.3892/ol.2014.2109

IL‑33 levels differentiate tuberculous pleurisy from malignant pleural effusions

Authors:
- Wei‑Xia Xuan
- Jian‑Chu Zhang
- Qiong Zhou
- Wei‑Bing Yang
- Li‑Jun Ma
View Affiliations

Affiliations: Department of Respiratory and Critical Medicine, The People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, P.R. China, Department of Respiratory Medicine, Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
Published online on: May 2, 2014 https://doi.org/10.3892/ol.2014.2109
Pages: 449-453

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tuberculous pleural effusions (TPEs) and malignant pleural effusions (MPEs) are difficult to differentiate between in certain clinical situations. Interleukin (IL)‑33 is a cytokine that participates in inflammatory responses and may have a role in pleural effusions. The present study aimed to investigate the concentrations and potential differential significance of IL‑33 in patients with TPE and MPE. IL‑33 levels in pleural effusion and serum samples were detected using sandwich enzyme‑linked immunosorbent assay in 23 patients with TPE and 21 patients with MPE. The concentration of IL‑33 (mean ± standard deviation) in the TPE patients (22.962±0.976 ng/l) was significantly higher than that in the MPE patients (12.603±5.153 ng/l; P<0.001; z=‑4.572); however, there was no significant difference in the serum level of IL‑33 in the patients with TPE compared with those with MPE (P>0.05). The concentration of IL‑33 in the pleural effusions was positively correlated with that in the serum samples in each group (TPE: r=0.563, P=0.05; MPE: r=0.535, P<0.05). The cut‑off value of pleural IL‑33 for TPE was 19.86 ng/l, which yielded a sensitivity of 0.869, a specificity of 0.905 and an area under the corresponding receiver operating characteristic curve of 0.903. The present study identified that the level of pleural IL‑33 is significantly increased in TPEs and may serve as a novel biomarker to differentiate between patients with TPE and MPE.

View Figures

View References

1	Hua CC, Chang LC, Chen YC and Chang SC: Proinflammatory cytokines and fibrinolytic enzymes in tuberculous and malignant pleural effusions. Chest. 116:1292–1296. 1999.
2	Wong CF, Yew WW, Leung SK, Chan CY, Hui M, Yeang C and Cheng AF: Assay of pleural fluid interleukin-6, tumour necrosis factor-alpha and interferon-gamma in the diagnosis and outcome correlation of tuberculous effusion. Respir Med. 97:1289–1295. 2003.
3	Qin XJ, Shi HZ, Huang ZX, Kang LF, Mo WN and Wu C: Interleukin-16 in tuberculous and malignant pleural effusions. Eur Respir J. 25:605–611. 2005.
4	Carriere V, Roussel L, Ortega N, et al: IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA. 104:282–287. 2007.
5	Schmitz J, Owyang A, Oldham E, et al: IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type2-associated cytokines. Immunity. 23:479–490. 2005.
6	Yasuda K, Muto T, Kawagoe T, et al: Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice. Proc Natl Acad Sci USA. 109:3451–3456. 2012.
7	van der Veerdonk FL and Netea MG: New insights in the immunobiology of IL-1 family members. Front Immunol. 4:1672013.
8	Milovanovic M, Volarevic V, Radosavljevic G, Jovanovic I, Pejnovic N, Arsenijevic N and Lukic ML: IL-33/ST2 axis in inflammation and immunopathology. Immunol Res. 52:89–99. 2012.
9	Tjota MY, Williams JW, Lu T, et al: IL-33-dependent induction of allergic lung inflammation by FcγRIII signaling. J Clin Invest. 123:2287–2297. 2013.
10	Bonilla WV, Fröhlich A, Senn K, et al: The alarmin interleukin-33 drives protective antiviral CD8⁺ T cell responses. Science. 335:984–989. 2012.
11	Cohen I, Rider P, Carmi Y, et al: Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc Natl Acad Sci USA. 107:2574–2579. 2010.
12	Ali S, Mohs A, Thomas M, et al: The dual function cytokine IL-33 interacts with the transcription factor NF-κB to dampen NF-κB-stimulated gene transcription. J Immunol. 187:1609–1616. 2011.
13	Light RW, Macgregor MI, Luchsinger PC and Ball WC Jr: Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 77:507–513. 1972.
14	Lee KS, Kim HR, Kwak S, et al: Association between elevated pleural interleukin-33 levels and tuberculous pleurisy. Ann Lab Med. 33:45–51. 2013.
15	Lefrançais E, Roga S, Gautier V, Gonzalez-de-Peredo A, Monsarrat B, Girard JP and Cayrol C: IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci USA. 109:1673–1678. 2012.
16	Barnes PF, Fong SJ, Brennan PJ, Twomey PE, Mazumder A and Modlin RL: Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis. J Immunol. 145:149–154. 1990.
17	Oboki K, Ohno T, Kajiwara N, Saito H and Nakae S: IL-33 and IL-33 receptors in host defense and diseases. Allergol Int. 59:143–160. 2010.
18	Okamoto M, Hasegawa Y, Hara T, Hashimoto N, Imaizumi K, Shimokata K and Kawabe T: T-helper type 1/T-helper type 2 balance in malignant pleural effusions compared to tuberculous pleural effusions. Chest. 128:4030–4035. 2005.
19	Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R and Smith DE: IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol. 20:1019–1030. 2008.
20	Bourgeois E, Van LP, Samson M, et al: The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol. 39:1046–1055. 2009.
21	Espinassous Q, Garcia-de-Paco E, Garcia-Verdugo I, et al: IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J Immunol. 183:1446–1455. 2009.
22	Feng CG, Kaviratne M, Rothfuchs AG, et al: NK cell-derived IFN-gamma differentially regulates innate resistance and neutrophil response in T cell-deficient hosts infected with Mycobacterium tuberculosis. J Immunol. 177:7086–7093. 2006.
23	Schierloh P, Yokobori N, Alemán M, et al: Mycobacterium tuberculosis-induced gamma interferon production by natural killer cells requires cross talk with antigen-presenting cells involving Toll-like receptors 2 and 4 and the mannose receptor in tuberculous pleurisy. Infect Immun. 75:5325–5337. 2007.
24	Caramori G, Lasagna L, Casalini AG, et al: Immune response to Mycobacterium tuberculosis infection in the parietal pleura of patients with tuberculous pleurisy. PLoS One. 6:e226372011.
25	Miller AM: Role of IL-33 in inflammation and disease. J Inflamm (Lond). 8:222011.
26	Joshi AD, Oak SR, Hartigan AJ, et al: Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages. BMC Immunol. 11:522010.
27	Choi YS, Choi HJ, Min JK, et al: Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood. 114:3117–3126. 2009.
28	Jovanovic I, Radosavljevic G, Mitrovic M, et al: ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immunol. 41:1902–1912. 2011.